✅ Öppen
Ingen deadline angiven
Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel
Tidsplan
Publicerad
2024-10-14
Deadline
—
Beskrivning
Tilldelat till: Bristol-Myers Squibb AB | Vinnarland: SWE | Beslutsdatum: 2024-10-07Z
Klassificering
CPV-koder
- 33600000 Läkemedel
Procedur
neg-wo-call
Om köparen
Region Skåne har 38 öppna upphandlingar på Agentanbud just nu, och 275 annonser i vår data.
Köper oftast: Medicinsk utrustning, läkemedel och hygienartiklar · Laboratorieutrustning, optisk utrustning och precisionsutrustning (exkl. glas) · Arkitekt-, bygg-, ingenjörs- och besiktningstjänster.
Flest kontrakt 2021–2024, enligt Upphandlingsmyndighetens statistik över 1953 kontrakterade anbud: Medtronic Aktiebolag (25) · B. Braun Medical Aktiebolag (22) · Accord Healthcare AB (22).
Liknande öppna upphandlingar
Rådata (JSON)
{
"title-proc": {
"swe": "Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel"
},
"publication-number": "619792-2024",
"contract-conclusion-date": [
"2024-10-08Z"
],
"winner-country": [
"SWE"
],
"organisation-country-buyer": [
"SWE"
],
"duration-period-value-lot": [
"4"
],
"framework-agreement-lot": [
"fa-wo-rc"
],
"place-of-performance-country-proc": [
"SWE"
],
"winner-identifier": [
"556092-9886"
],
"procedure-type": "neg-wo-call",
"classification-cpv": [
"33600000",
"33600000"
],
"publication-date": "2024-10-14+02:00",
"buyer-name": {
"swe": [
"Region Skåne, Koncernstab inköp och ekonomistyrning"
]
},
"winner-decision-date": [
"2024-10-07Z"
],
"contract-nature-main-proc": "supplies",
"links": {
"xml": {
"MUL": "https://ted.europa.eu/en/notice/619792-2024/xml"
},
"pdf": {
"BUL": "https://ted.europa.eu/bg/notice/619792-2024/pdf",
"SPA": "https://ted.europa.eu/es/notice/619792-2024/pdf",
"CES": "https://ted.europa.eu/cs/notice/619792-2024/pdf",
"DAN": "https://ted.europa.eu/da/notice/619792-2024/pdf",
"DEU": "https://ted.europa.eu/de/notice/619792-2024/pdf",
"EST": "https://ted.europa.eu/et/notice/619792-2024/pdf",
"ELL": "https://ted.europa.eu/el/notice/619792-2024/pdf",
"ENG": "https://ted.europa.eu/en/notice/619792-2024/pdf",
"FRA": "https://ted.europa.eu/fr/notice/619792-2024/pdf",
"GLE": "https://ted.europa.eu/ga/notice/619792-2024/pdf",
"HRV": "https://ted.europa.eu/hr/notice/619792-2024/pdf",
"ITA": "https://ted.europa.eu/it/notice/619792-2024/pdf",
"LAV": "https://ted.europa.eu/lv/notice/619792-2024/pdf",
"LIT": "https://ted.europa.eu/lt/notice/619792-2024/pdf",
"HUN": "https://ted.europa.eu/hu/notice/619792-2024/pdf",
"MLT": "https://ted.europa.eu/mt/notice/619792-2024/pdf",
"NLD": "https://ted.europa.eu/nl/notice/619792-2024/pdf",
"POL": "https://ted.europa.eu/pl/notice/619792-2024/pdf",
"POR": "https://ted.europa.eu/pt/notice/619792-2024/pdf",
"RON": "https://ted.europa.eu/ro/notice/619792-2024/pdf",
"SLK": "https://ted.europa.eu/sk/notice/619792-2024/pdf",
"SLV": "https://ted.europa.eu/sl/notice/619792-2024/pdf",
"FIN": "https://ted.europa.eu/fi/notice/619792-2024/pdf",
"SWE": "https://ted.europa.eu/sv/notice/619792-2024/pdf"
},
"pdfs": {
"SWE": "https://ted.europa.eu/sv/notice/619792-2024/pdfs"
},
"html": {
"BUL": "https://ted.europa.eu/bg/notice/-/detail/619792-2024",
"SPA": "https://ted.europa.eu/es/notice/-/detail/619792-2024",
"CES": "https://ted.europa.eu/cs/notice/-/detail/619792-2024",
"DAN": "https://ted.europa.eu/da/notice/-/detail/619792-2024",
"DEU": "https://ted.europa.eu/de/notice/-/detail/619792-2024",
"EST": "https://ted.europa.eu/et/notice/-/detail/619792-2024",
"ELL": "https://ted.europa.eu/el/notice/-/detail/619792-2024",
"ENG": "https://ted.europa.eu/en/notice/-/detail/619792-2024",
"FRA": "https://ted.europa.eu/fr/notice/-/detail/619792-2024",
"GLE": "https://ted.europa.eu/ga/notice/-/detail/619792-2024",
"HRV": "https://ted.europa.eu/hr/notice/-/detail/619792-2024",
"ITA": "https://ted.europa.eu/it/notice/-/detail/619792-2024",
"LAV": "https://ted.europa.eu/lv/notice/-/detail/619792-2024",
"LIT": "https://ted.europa.eu/lt/notice/-/detail/619792-2024",
"HUN": "https://ted.europa.eu/hu/notice/-/detail/619792-2024",
"MLT": "https://ted.europa.eu/mt/notice/-/detail/619792-2024",
"NLD": "https://ted.europa.eu/nl/notice/-/detail/619792-2024",
"POL": "https://ted.europa.eu/pl/notice/-/detail/619792-2024",
"POR": "https://ted.europa.eu/pt/notice/-/detail/619792-2024",
"RON": "https://ted.europa.eu/ro/notice/-/detail/619792-2024",
"SLK": "https://ted.europa.eu/sk/notice/-/detail/619792-2024",
"SLV": "https://ted.europa.eu/sl/notice/-/detail/619792-2024",
"FIN": "https://ted.europa.eu/fi/notice/-/detail/619792-2024",
"SWE": "https://ted.europa.eu/sv/notice/-/detail/619792-2024"
},
"htmlDirect": {
"BUL": "https://ted.europa.eu/bg/notice/619792-2024/html",
"SPA": "https://ted.europa.eu/es/notice/619792-2024/html",
"CES": "https://ted.europa.eu/cs/notice/619792-2024/html",
"DAN": "https://ted.europa.eu/da/notice/619792-2024/html",
"DEU": "https://ted.europa.eu/de/notice/619792-2024/html",
"EST": "https://ted.europa.eu/et/notice/619792-2024/html",
"ELL": "https://ted.europa.eu/el/notice/619792-2024/html",
"ENG": "https://ted.europa.eu/en/notice/619792-2024/html",
"FRA": "https://ted.europa.eu/fr/notice/619792-2024/html",
"GLE": "https://ted.europa.eu/ga/notice/619792-2024/html",
"HRV": "https://ted.europa.eu/hr/notice/619792-2024/html",
"ITA": "https://ted.europa.eu/it/notice/619792-2024/html",
"LAV": "https://ted.europa.eu/lv/notice/619792-2024/html",
"LIT": "https://ted.europa.eu/lt/notice/619792-2024/html",
"HUN": "https://ted.europa.eu/hu/notice/619792-2024/html",
"MLT": "https://ted.europa.eu/mt/notice/619792-2024/html",
"NLD": "https://ted.europa.eu/nl/notice/619792-2024/html",
"POL": "https://ted.europa.eu/pl/notice/619792-2024/html",
"POR": "https://ted.europa.eu/pt/notice/619792-2024/html",
"RON": "https://ted.europa.eu/ro/notice/619792-2024/html",
"SLK": "https://ted.europa.eu/sk/notice/619792-2024/html",
"SLV": "https://ted.europa.eu/sl/notice/619792-2024/html",
"FIN": "https://ted.europa.eu/fi/notice/619792-2024/html",
"SWE": "https://ted.europa.eu/sv/notice/619792-2024/html"
}
},
"winner-name": {
"swe": [
"Bristol-Myers Squibb AB"
]
},
"notice-title": {
"hun": "Svédország – Gyógyszerészeti termékek – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
"lav": "Zviedrija – Farmācijas izstrādājumi – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
"swe": "Sverige – Läkemedel – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
"gle": "An tSualainn – Pharmaceutical products – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
"ell": "Σουηδία – Φαρμακευτικά προϊόντα – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
"spa": "Suecia – Productos farmacéuticos – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
"est": "Rootsi – Ravimid – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
"nld": "Zweden – Farmaceutische producten – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
"fin": "Ruotsi – Farmaseuttiset tuotteet – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
"pol": "Szwecja – Produkty farmaceutyczne – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
"hrv": "Švedska – Farmaceutski proizvodi – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
"ces": "Švédsko – Léčivé přípravky a zdravotnické prostředky – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
"dan": "Sverige – Lægemidler – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
"ron": "Suedia – Produse farmaceutice – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
"por": "Suécia – Produtos farmacêuticos – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
"slk": "Švédsko – Farmaceutické výrobky – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
"fra": "Suède – Produits pharmaceutiques – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
"mlt": "L-Iżvezja – Prodotti farmaċewtiċi – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
"deu": "Schweden – Arzneimittel – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
"lit": "Švedija – Farmacijos produktai – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
"ita": "Svezia – Prodotti farmaceutici – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
"bul": "Швeция – Фармацевтични продукти – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
"slv": "Švedska – Farmacevtski proizvodi – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
"eng": "Sweden – Pharmaceutical products – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel"
},
"buyer-city": {
"mul": [
"KRISTIANSTAD"
]
}
}